Advice
Following SMC collaboration with NICE on TA900: tixagevimab plus cilgavimab for preventing COVID-19:
tixagevimab plus cilgavimab (Evusheld®) is not recommended for use within NHSScotland.
Indication under review: Pre-exposure prophylaxis of COVID-19 in adults who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and:
- who are unlikely to mount an adequate immune response to COVID-19 vaccination or
- for whom COVID-19 vaccination is not recommended.
Download detailed advice236KB (PDF)
Medicine details
- Medicine name:
- tixagevimab / cilgavimab (Evusheld)
- SMC ID:
- SMC2580
- Indication:
Pre-exposure prophylaxis of COVID-19 in adults who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and:
- who are unlikely to mount an adequate immune response to COVID-19 vaccination or
- for whom COVID-19 vaccination is not recommended.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Not recommended
- Date advice published
- 14 June 2023